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Abstract DNA integrity is constantly challenged by endoge-
nous and exogenous factors that can alter the DNA sequence,
leading to mutagenesis, aberrant transcriptional activity, and
cytotoxicity. Left unrepaired, damaged DNA can ultimately
lead to the development of cancer. To overcome this threat, a
series of complex mechanisms collectively known as the DNA
damage response (DDR) are able to detect the various types of
DNA damage that can occur and stimulate the appropriate re-
pair process. Each DNA damage repair pathway leads to the
recruitment, upregulation, or activation of specific proteins
within the nucleus, which, in some cases, can represent attrac-
tive targets for molecular imaging. Given the well-established
involvement of DDR during tumorigenesis and cancer therapy,
the ability to monitor these repair processes non-invasively
using nuclear imaging techniques may facilitate the earlier de-
tection of cancer and may also assist in monitoring response to
DNA damaging treatment. This review article aims to provide
an overview of recent efforts to develop PET and SPECT ra-
diotracers for imaging of DNA damage repair proteins.
Keywords DNAdamage . PET . SPECT .Molecular
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Introduction
The DNA double helix within every cell of the human body is
constantly exposed to damaging agents, and, consequently,
tens of thousands of DNA lesions occur per cell each day
[1]. If a lesion is not correctly repaired, it may cause the cell
to become senescent, apoptotic, or even malignant. Over the
last few decades, a multitude of endogenous and exogenous
causes of DNA damage have been identified [2, 3].
Endogenous processes are responsible for the vast majority
of DNA damage and can be divided into three main catego-
ries: oxidative (i.e. produced by reactive oxygen species), hy-
drolytic (e.g. deamination of cytosine to uracil), and alkylation
reactions (e.g. methylation of the N7-position of guanine res-
idues) [4]. As exogenous sources of DNA damage, ultraviolet
light and ionizing radiation have been found to be among the
most prevailing factors, causing single-strand breaks (SSBs)
and double-strand breaks (DSBs), respectively [5]. In addi-
tion, certain chemotherapy drugs used for cancer treatment,
industrial chemicals, and carcinogens associated with tobacco
products are well recognised to cause DNA damage.
The recognition and repair of DNA damage is achieved by
a set of complex yet finely tuned DNA damage response
(DDR) signalling pathways that inhibit cell cycle progression
and repair DNA lesions by a variety of mechanisms (Fig. 1).
The excellent level of control over these processes ultimately
minimises genomic instability and impedes tumorigenesis [6].
Defects in this defensive mechanism have been found to occur
with significantly higher prevalence in many human cancers
compared to normal tissues [7–11]. As a consequence, exten-
sive DNA damage and DDR signalling is present and critical-
ly important in virtually all stages of tumour development,
from dysplasia to advanced metastatic disease [12, 13].
Therefore, the ability to monitor DDR in vivo in a non-
invasive manner via molecular imaging is an attractive pros-
pect as the information obtained from these techniques could
facilitate the earlier detection of several cancer types.
Furthermore, as most cancer therapies are designed to cause
DNA damage, these techniques may also provide a rapid and
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broadly applicable means of evaluating response to therapy. In
this review article, we discuss potentially valuable bio-
markers, which arise during the major cellular responses to
SSBs and DSBs, and we also evaluate recent efforts to mon-
itor these biomarkers non-invasively in vivo using PET and
SPECT radiotracers.
Single-strand break repair mechanisms
The repair of SSBs in DNA is mainly facilitated by base ex-
cision repair (BER) [14]. Deficiencies and mutations of pro-
teins in this pathway are linked to genomic instability, aging,
and cancer [15]. BER has two sub-pathways referred to as
short-patch repair (Fig. 2) and long-patch repair; the former
being responsible for up to 90% of all BER [16]. In brief,
short-patch BER is based on five major steps: (i) recognition
of the damaged base by a DNA glycosylase and the conse-
quent removal of the base, creating an apurinic or
apyrimidinic (AP) site intermediate, (ii) incision of the abasic
site by an AP endonuclease (APE) or AP lyase, (iii) removal
of the remaining sugar fragment by a lyase or phosphodiester-
ase, (iv) filling of the remaining gap by a DNA polymerase
(commonly, DNA polymerase β, POLB) with the correct nu-
cleotide, and finally (v) sealing of the remaining nick by a
DNA ligase (LIG1 or LIG3/XRCC1 complex) [17].
Among the many sensors involved in the BER repair of
SSBs, poly(ADP-ribose) polymerase 1 (PARP-1) is particu-
larly influential in this process [18–21]. Upon binding to
nicked DNA, PARP-1 cleaves nicotinamide adenine dinucle-
otide (NADb), whereupon it catalyses the polymerisation of
ADP-ribose units into long, branched chains of poly(ADP-
ribose) (PAR) [22]. While the chief target for poly(ADP-
ribosylation) is PARP-1 itself via automodification, other
DNA damage repair proteins and histones are also
PARylated. PAR is thereafter responsible for the recruitment
of additional DDR proteins which cooperate for the comple-
tion of SSB repair [23–25]. Small molecule inhibitors of
PARP-1 have the ability to disrupt the BER repair pathway,
leading to collapsed replication forks and ultimately DSBs
upon replication [26–30]. Several key studies have since
shown that normal cells can compensate in these circum-
stances by relying on other repair mechanisms, such as ho-
mologous recombination (HR), which act to restore the orig-
inal DNA sequence [31]. In accordance with these observa-
tions, studies focused on the genetic removal of PARP-1 have
found no significant effect upon the frequency of tumour
Fig. 2 A simplified diagram showing the major steps in short-patch base
excision repair pathway. In the presence of DNA damage, PARP-1 is
activated upon binding to SSBs, leading to recruitment of BER
proteins. These proteins will then identify and repair the damage
Fig. 1 A simplified overview of the DNA damage response and the main
targets involved. BER, Base Excision Repair; HR, Homologous
Recombination; NHEJ, Non-Homologous End Joining; LIG3, DNA
Ligase 3; XRCC1, X-ray repair cross-complementing protein 1; PARP-
1, poly (ADP-ribose) polymerase 1; BRCA1/2, Breast Cancer 1/2; ATM,
Ataxia Telangiectasia Mutated; DNA-PK, DNA-dependent protein
kinase catalytic subunit
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development [31]. Notably, however, cancer cells with defects
in HR (most commonly arising from mutations of BRCA1
and BRCA2 proteins) have exhibited vastly increased sensi-
tivity to PARP-1 inhibitors [32, 33]. In such cases, damaged
DNA either persists unrepaired or is subjected to a more error-
prone DNA repair mechanism (e.g. non-homologous end
joining [NHEJ], or single-strand annealing [SSA]) [34].
Both scenarios will ultimately trigger cell death via apoptosis.
These discoveries have stimulated intensive research efforts
focused on evaluating the therapeutic potential of PARP-1
inhibitors, principally for breast and ovarian cancers in
BRCA-mutation carriers [35].
Expression levels of the PARP1 enzyme are significantly
elevated in a variety of cancer types [36–42] compared with
normal tissues, due to genomic stress, rapid proliferation, and
abnormal metabolism. Furthermore, this enzyme has been
found to have value as a prognostic indicator, particularly as
the upregulation of PARP1 has been linkedwith reduced over-
all survival [38]. This is most notably the case in brain malig-
nancies which frequently contain elevated levels of PARP1
while healthy brain tissue has extremely low basal expression
of this enzyme [40, 41]. These observations strongly indicate
that PARP1 is a valuable biomarker of DNA damage which
could be detected by PETor SPECT imaging. Furthermore, as
PARP1 is a well-established therapeutic target, radiotracers
based on PARP-1 inhibitors could find application as compan-
ion diagnostics during therapy, since they could provide useful
information during the drug development process regarding
important aspects of in vivo behaviour, such as
biodistribution, pharmacokinetics, and target engagement.
Double-strand break repair mechanisms
Double-strand breaks are the most harmful form of DNA
damage as just a single occurrence can potentially result in
chromosomal translocation or cell death [43]. The repair of
DSBs is executed by two main pathways: HR and NHEJ
(Fig. 3) [44].
HR is initiated when ataxia telangiectasia mutated (ATM)
kinase protein binds to a DSB, whereupon it is activated and
triggers the DNA damage response [45]. In the HR pathway,
there are several protagonists, including the MRN complex
(Mre11, Rad50, Nbs1), RPA, Rad51, and BRCA1/2. The
MRN complex is responsible for the resection of 5’-3’ ends
upon DSB recognition which are then coated with RPA [46].
Recombination is performed by Rad51, which replaces RPA
in a BRCA1/2-dependant manner to assemble presynaptic
Rad51 filaments [47]. A displacement loop (D-Loop) contain-
ing the novel heteroduplex DNA is then formed via DNA
strand exchange between the target DNA and the Rad51 fila-
ment. Lastly, the broken 3’ end primes DNA synthesis using
the duplex DNA as a template [48]. Several HR proteins are
mutated in cancer, including BRCA1/2 in breast and ovarian
cancer. These mutations can lead to inactivation of sub-
pathways of HR, thereby driving other genetic effects respon-
sible for the development of cancer.
NHEJ involves binding of the Ku70-Ku80 protein hetero-
dimer to the DNA lesion, followed by the attachment of DNA-
dependent protein kinase catalytic subunit (DNA-PKcs). The
resulting DNA-PK holoenzyme binds and phosphorylates the
protein Artemis, which cleaves the single-stand overhangs of
DNA. Lastly, a complex of proteins, including DNA ligase 4
(LIG4), XRCC4 and XLF then complete the process by join-
ing the DNA ends [49]. While NHEJ is less accurate than HR,
it can be performed in the absence of undamaged sister chro-
matid DNA [50]. As with HR, NHEJ is important for genomic
integrity since alterations of the Ku complex or LIG4 can
cause genome rearrangements [51].
Shortly after a DSB event, the X isoform of the histone
H2A is phosphorylated at the serine-139 position by members
of the phosphoinositide 3-kinase (PI3K)-related protein kinase
(PIKK) family such as ATM, ATR, and DNA-PKcs [52, 53].
The resulting protein, known as γH2AX, forms foci (Fig. 4
[54]) containing hundreds of copies (measuring up to 40Mbp)
[55] around each individual break site. Here, γH2AX is in-
volved in the recruitment of most of the other DNA repair
proteins discussed above, whereupon it promotes re-joining
of DNA remnants [56, 57]. In addition, γH2AX regulates cell
cycle checkpoints to ensure completion of DNA repair and
chromatin structure around the affected site. After the damage
is repaired, γH2AX is removed, restoring the affected parts of
chromatin and preserving both genetic and epigenetic infor-
mation [58]. The mechanism of removal is still not fully un-
derstood, but it has been proposed that it is mediated by de-
phosphorylation of γH2AX by phosphatases and through his-
tone exchange in the chromatin [59, 60].
Phosphorylation of H2AX at serine-139 is abundant, rapid,
and correlates well with each DSB, and consequently γH2AX
has become the most commonly probed marker of DNA
DSBs. γH2AX has added clinical value as it has been found
to be expressed during the early development of most cancers.
This includes bladder, breast, cervix, colon, lung, ovaries,
pancreas, and skin cancers [57, 61, 62]. Furthermore, in clin-
ical samples, high numbers of γH2AX foci have been corre-
lated with poor outcomes [63]. Taken together, these proper-
ties render γH2AX an attractive target for quantitative, high
sensitivity molecular imaging techniques.
Methods for DNA damage detection: state-of the-art
One of the most well-established methods of probing DNA
damage in vitro is pulsed-field gel electrophoresis (PFGE)
[64]. While conventional gel electrophoresis techniques can
resolve DNA fragments up to roughly 50 kb, the introduction
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of an alternating voltage gradient in PFGE is advantageous as
it permits resolution of larger DNA fragments up to 10 Mb
[65]. Another common electrophoresis-based method is the
comet assay which, following separation of DNA fragments,
leads to comet-like shapes which can be observed by fluores-
cence microscopy [66, 67]. The relative intensities of the head
(undamaged DNA) and tail (damaged DNA) regions of each
comet can be used to quantify SSBs and DSBs in individual
eukaryotic cells; although this assay does not reveal the size of
individual DNA fragments. Both PGFE and the comet assay
have a common drawback as they rely on the extraction of
damaged DNA from lysed cells prior to analysis.
The development of confocal immunofluorescence micros-
copy has since permitted visualisation of DDR proteins within
the nuclear compartment of single cells and, in doing so, has
helped to elucidate several key DNA repair mechanisms. For
Fig. 3 A simplified diagram of
the principal steps in the repair of
double strand breaks by
homologous recombination (HR)
and non-homologous end joining
(NHEJ)
Fig. 4 Immunostaining of fine-
needle aspiration tumour
specimens from a patient with
non-Hodgkin’s lymphoma
deposits reveals the appearance of
γH2AX (green) and 53BP1 foci
within the nucleus (DAPI, blue)
20 min following irradiation.
Reproduced with permission
from [54]
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example, γH2AX and 53BP1 foci are routinely used to enu-
merate the extent of DSB repair following genotoxic stimuli
[68, 69].
More recently, live cell imaging has provided valuable in-
formation on the kinetics of DNA repair in vitro [70]. Most
live cell imaging experiments rely on transfection of the cell-
of-interest with a gene coding for a chimeric fusion protein of
the DDR protein-of-interest coupled to a fluorescent protein
such as GFP, YFP, or mCherry. Examples include the use of a
53BP1-mCherry construct to study the kinetics of 53BP1 re-
cruitment to DSB repair foci and their dissolution [71], and the
use of Mdc1-, ATR-, and Chk1-GFP fusion proteins to probe
the effects of ultraviolet laser radiation [72]. In 2009, Hilario
et al. characterised the dynamics of Rad51 filaments and their
assembly and disassembly to DNA by single molecule fluo-
rescence microscopy [73]. This was one of the first demon-
strations of a real-time study of Rad51 nucleoprotein filament
formation, providing details on the rate of filament growth as
well as the rate of DNA extension upon Rad51 association.
All of these studies have provided tremendous insight to-
ward the spatiotemporal dynamics of DNA damage repair.
The various genetic, biochemical, and molecular biological
approaches that have been used to date have characterised in
detail the different repair pathways involved. However, much
more effort is still required to gain important insight such as
how functional pathways are formed by coordination between
different repair players, as well as the mechanisms involved in
the interaction between these pathways and other cellular
processes.
In an effort to extend some of the live cell DDR imaging
techniques to an in vivo preclinical setting, Li et al. transfected
H322 lung cancer cells with N- and C-terminal fragments of
firefly luciferase genes fused with H2AX and MDC1, respec-
tively [74]. Upon irradiation of the cells and formation of
DSBs, MDC1 is recruited to phosphorylated H2AX in foci
around the DSB, thereby bringing into close proximity both
halves of the luciferase protein and allowing the formation of a
visible light signal upon addition of luciferin. The same au-
thors also showed that this approach is viable for use in mice
bearing subcutaneous xenografts of transfected H322 cells
[74]. An initial DDR response was observed in the first day
after irradiation (6 Gy) of xenografts. A consecutive apoptotic
response, reaching a maximum at 10 days post-irradiation,
was also observed.
Later, a luciferase-based reporter was developed to non-
invasively test ATM activity in cells and was found to undergo
increased activation uponATM inhibition in a dose-dependent
manner, thus enabling the validation of ATM inhibitors in
addition to quantifying ATMkinase activity [75]. This method
could potentially allow the successful characterisation of
ATM inhibitors used in therapeutic regimes, and was also
evaluated for in vivo use. Both of these elegant methods allow
repeated probing of aspects of the DDR, yet have the main
disadvantage that they cannot be translated into clinical use,
since transfection of the target cells is a necessity.
A much more advantageous prospect for translation to the
clinic is the use of PETor SPECT imaging agents, particularly
as they do not rely on modification of the target cell. These
functional imaging techniques have excellent sensitivity in
comparison to other clinical imaging modalities and are rou-
tinely used for in vivo tracking of biomolecular processes. The
principal advantages that in vivo imaging of DDR can offer
over conventional tissue biopsies are: (1) the ability to analyse
larger tissue volumes compared with a small, potentially un-
representative sample, (2) an improved insight into tumour
heterogeneity, (3) the lack of need for an invasive operation
to access the area of interest, which completely removes the
risk of serious complications related to infection,
haemorrhaging etc., and (4) the option to perform repeated
imaging of the same area which would allow longitudinal
assessment.
Imaging PARP-1 with PET and SPECT
Because of the well-established role of PARP-1 as a mediator
in the repair of DNA SSBs, it represents an attractive biomark-
er for PET and SPECT imaging. Consequently, over the last
decade, there have been several attempts to develop
radiolabelled imaging agents in order to permit visualisation
of this DDR protein:
[11C]-PARP-1 radiotracers
The first example of a PET radiotracer based on a PARP-1
inhibitor was reported by Tu et al. in 2005 [76]. In this case, a
phenanthridinone derivative known as PJ34 was selected as it
can block NAD+ from its binding site on the activated form of
the PARP-1 enzyme. PJ34 was radiolabelled with carbon-11
via a base-catalysed reaction with [11C]methyl iodide and the
resulting radiotracer, [11C]PJ34 (Table 1), was used in a rat
model of type 1 diabetes to assess its ability to detect early
stages of necrosis in pancreatic islets. Promisingly, [11C]PJ34
accumulated significantly more in necrotic pancreases com-
pared with the pancreases of healthy rats at both 5 and 30 min
after injection of the radiotracer.
[18F]-PARP-1 radiotracers
A handful of PARP inhibitors radiolabelled with fluorine-18
have also been evaluated and, in some cases, have shown
good potential. Initial studies were focused on the preparation
of radiofluorinated pirenzepine derivatives and related metab-
olites due to their ability to inhibit PARP-1 activity [84]. An
early example, [18F]-4 (Table 1), reported by Riss et al. in
2009 exhibited a moderate binding affinity (Ki) of 200 nM,
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good stability in human serum, and a logD7.4 value of 1.4,
which would likely aid in penetration of cellular membranes
although subsequent in vivo evaluation of this radiotracer has
not been reported [84].
Weissleder and colleagues subsequently reported an 18F-
radiolabeled derivative of the much-studied PARP inhibitor
Olaparib, [18F]-BO (Fig. 5, Table 1), which was synthesised
via a [4+2] inverse-electron-demand Diels-Alder cycloaddi-
tion reaction between a tetrazine-modified Olaparib derivative
and an 18F prosthetic group based on trans-cyclooctene
[81–83]. The half maximal inhibitory concentration of the
resulting compound (IC50 = 17.9±1.1 nM) was only moder-
ately reduced relative to unmodified Olaparib (IC50 = 5 nM)
[87], which indicates that minor chemical modifications to the
piperazine moiety of Olaparib are only minimally disruptive
to PARP-1 binding. In addition to showing PARP-1-mediated
cellular uptake in in vitro assays, [18F]-BO was also shown in
PET experiments to accumulate specifically in PARP-1 over-
expressing MDA-MB-468 breast cancer xenografts in mice
[82]. Reiner et al. later demonstrated that [18F]-BO could ac-
curately measure the extent of PARP-1 expression in a variety
of xenograft tumour models in mice and showed that uptake
of [18F]-BO in ovarian (A2780) xenograft tumours was mark-
edly reduced after administration of Olaparib (Fig. 6) [83].
These compelling findings indicate the potential of this radio-
tracer to be used as a companion diagnostic for measuring
therapeutic drug inhibition in an in vivo setting.
In an effort to create a dual-modality PARP imaging agent,
Carlucci et al. developed an Olaparib derivative ([18F]PARPi-
FL, Fig. 5, Table 1) containing both BODIPY-FL dye and a
fluorine-18 atom which was introduced via an 18F/19F trans-
fluorination exchange reaction [77]. While relatively facile,
this method of radiolabeling led to low specific activities
(2.9±0.7 or 9 mCi/μmol using manual and automated synthe-
sis methods, respectively) compared to the other PARP inhib-
itors discussed herein. Furthermore, [18F]PARPi-FL was sub-
ject to rapid metabolic defluorination, which resulted in high
bone uptake (∼10-15%ID/g). This imaging agent was capable,
however, of distinguishing U87 glioblastoma xenografts (0.78
±0.1%ID/g at 90 min post injection) in small animal PET
imaging and ex vivo biodistribution experiments, which was
effectively blocked (0.15±0.06%ID/g) with an excess of
Olaparib.
While [18F]-BO and [18F]PARPi-FL each contain bulky
chemical substituents, a more recent study has resulted in an
[18F]-radiolabeled compound which is structurally more con-
sistent with the parent molecule, Olaparib [78]. This radiotrac-
er, [18F]PARPi (Fig. 5, Table 1), has an attractive IC50 value of
2.83 nM and, in contrast to [18F]PARPi-FL, the aromatic
carbon-[18F]fluorine bond exhibited high stability, remaining
largely intact in human serum samples over 4 h. In ex vivo
biodistribution experiments performed at 2 h post injection,
this radiotracer achieved uptake values of 1.82±0.21%ID/g inTa
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subcutaneous U87 xenograft tumours, whichwas proven to be
mediated by PARP-1. In an orthotopic glioblastoma model,
[18F]PARPi was also shown to selectively accumulate in
PARP-1-expressing U251-MG tumours (Fig. 7), indicating
the ability of this radiotracer to pass through the blood–brain
barrier. In a similar manner to the other radiotracers derived
from Olaparib discussed herein, the majority of [18F]PARPi
excretion occurs via the hepatobiliary clearance pathway.
In 2014, Zhou et al. showed that radiofluorinated deriva-
tives of the benzimidazole NU1085 and its structural near-
relative AG014361 also had high inhibitory potency against
the PARP-1 enzyme [80]. One of these structures, known as
[18F]FluorThanatrace ([18F]FTT; Fig. 8, Table 1), was pre-
pared in considerably higher specific activities compared to
the other PARP-1 radiotracers discussed herein (5,500-
18,000 mCi/μmol) and was also found to have a reasonable
IC50 value of 6.3±1.3 nM. Small animal PET/CT experiments
comparing MDA-MB-231 (low PARP-1 expressing) and
MDA-MB-468 (high PARP-1 expressing) xenograft tumours
revealed PARP-1 mediated tumour uptake which could be
blocked following pre-injection of either Olaparib or
[19F]FTT. Edmonds et al. also recently used this compound,
albeit at a significantly lower specific activity (<2,200 mCi/
μmol), and showed that uptake of this radiotracer in a variety
of xenograft tumour models in mice could be correlated with
intrinsic PARP-1 expression levels. This study also provided
compelling evidence that uptake of [18F]FTT is mediated sole-
ly by PARP-1, which was concluded after in vitro uptake
experiments in PARP-2 knock-out cells revealed specific
binding at levels comparable to wild-type cells [79].
Radioiodinated PARP-1 radiotracers
There have been several recent examples of PARP-1 inhibitors
labeled with radioisotopes of iodine for both PET and SPECT
imaging applications [85, 86]. Two of these reports describe
Fig. 5 A selection of 18F-
radiolabelled PARP-1 inhibitors
derived from Olaparib
Fig. 6 Reiner et al. demonstrated that measuring response to Olaparib
treatment is possible using [18F]-BO [83]. Left: In mice bearing A2780
tumour xenografts, tumour-to-muscle contrast ratios markedly reduce
following administration of Olaparib. Right: Representative PET/CT
images pre- and post-Olaparib administration. Reproduced with
permission from [83]
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the development of multiple radioiodinated Olaparib deriva-
tives; however, each focuses on the evaluation of a single
structurally identical compound, [123/124/131I]-I2-PARPi
(Table 1). The Reiner group demonstrated the feasibility of
using this compound to detect glioblastoma by targeting
orthotopic U251 MG xenografts in mice [86]. SPECT/CT
and PET/CT studies involving [131I]-I2-PARPi and [124I]-I2-
PARPi, respectively, enabled visualisation of PARP-
expressing tumour tissue that could be readily delineated from
normal brain tissue. In particular, [124I]-I2-PARPi yielded at-
tractive tumour-to-brain and tumour-to-muscle ratios of 40.0
±6.3 and 13.7±4.1, respectively, at 2 h post-injection. Zmuda
et al. also demonstrated in a subcutaneous U87MG-Luc2 glio-
blastoma xenograft model (WHO grade IV) the ability of
[123I]-I2-PARPi to be retained within tumour tissue and corre-
lated this uptake to the expression of PARP and the prolifera-
tive marker Ki67 [85]. In this case, a peak tumour-to-muscle
ratio of 5.61±1.99 was achieved at 2 h post injection.
Mach and colleagues have reported two radioiodinated
benzimidazole derivatives, [125I]KX1 [88] and [125I]KX-02-
019 [89] (Fig. 8), which bear close structural resemblance to
FluorThanatrace. The ability of [125I]KX1 tomeasure PARP-1
expression in vivo was tested in mice bearing subcutaneous
HCC1937 (high PARP-1) and MDA-MB-231 (low PARP-1)
human breast cancer xenografts [88]. At 2 h post injection,
significantly higher uptake of [125I]KX1 was observed in
HCC1937 tumours (reaching approximately 5%ID/g); how-
ever, no blocking effect was observed following administra-
tion of olaparib suggesting a lack of specificity. It was postu-
lated that differences in the pharmacokinetic profiles of these
two agents could prevent a blocking effect, although no addi-
tional attempts at blocking with unlabelled KX1 were report-
ed. Autoradiography analysis of HCC1937 tumour tissue at
2 h post injection did however reveal a reduction of signal
following Olaparib treatment compared to non-treated mice.
It could, therefore, be envisaged that this agent, and analogous
agents containing iodine-123/124/131, could serve as com-
panion diagnostic agents during therapy and may assist in
patient stratification.
Imaging γH2AX with PET and SPECT
The ability to monitor γH2AX expression in vivo may help to
detect certain cancers earlier in their development compared
with existing diagnostic methods, facilitating timelier inter-
vention and improved survival. Furthermore, it would also
allow indirect monitoring of the DSBs caused by radiotherapy
and some chemotherapeutic agents, thus permitting rapid de-
termination of therapeutic efficacy. Consequently, a concerted
effort is now underway to develop a non-invasive means of
quantifying γH2AX expression levels in vivo using both PET
and SPECT imaging techniques.
As an imaging biomarker, γH2AX has several advantages
compared with other DDR proteins. For example, H2AX can
be phosphorylated throughout the cell cycle, whereas 53BP1,
Fig. 7 Top: In orthotopic
glioblastoma-bearing mice, PET/
MRI images showed pronounced
uptake of [18F]PARPi at 2 h post-
injection. Bottom: Pre-injection
with a 500-fold excess of
Olaparib effectively reduced
tumour uptake of [18F]PARPi,
providing evidence of specificity
of the imaging agent for PARP-1.
Reproduced with permission
from [78]
Fig. 8 A selection of radiolabelled PARP-1 inhibitors based on
benzimidazole derivatives
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MRE11, and NBS1 are dissociated from DNA damage foci
during mitosis [56, 90, 91]. Furthermore, 53BP1 is known to
form DNA repair foci via translocation during, which its ex-
pression levels do not change dramatically. While PET and
SPECT imaging are very sensitive imaging techniques, they
cannot distinguish between the various intracellular locations
of proteins such as 53BP1. In stark contrast, γH2AX is a new
species which is induced by phosphorylation following DSB
formation. This on/off switch-like behaviour renders the
γH2AX amuchmore attractive imaging target, i.e. under phys-
iological conditions, cells express little to no yH2AX, whereas
upon DSB formation, γH2AX is formed very rapidly.
γH2AX radiotracer development
While anti-γH2AX antibodies are now used routinely in
ex vivo assays to quantify the number of γH2AX foci within
permeabilised cell populations, the translation of such
antibody-based imaging agents into an in vivo setting requires
the addition of the cell penetrating peptide (CPP) [92, 93]
named BTAT ,^ which is derived from the transactivator of
transcription protein of the HIV-1 virus [94–98]. This
arginine-rich peptide has been shown to promote the cellular
internalisation of antibodies and a variety of other species,
including peptides [99], nanoparticles [100], and liposomes
[101]. The precise mechanism(s) of internalisation have been
the focus of several studies, many of which have provided
strong evidence that electrostatic interaction of the positively
charged CPP with negatively charged heparin sulfate proteo-
glycans on the periphery of the cell membrane plays an im-
portant role in promoting internalisation via endocytosis [102,
103]. However, it is worth noting that none of these studies
have been able to inhibit completely this process, which sug-
gests that other mechanisms, including energy-independent
direct translocation, could also be a contributing factor to this
phenomenon. Of the endocytotic pathways that could be re-
sponsible, virtually all known possibilities have been impli-
cated, including macropinocytosis [104], clathrin- [105], and
caveolin-mediated endocytosis [106]. It is of course possible,
if not likely, that more than one mechanism of TAT-
internalisation exists and therefore these studies are not nec-
essarily contradictory. The TAT peptide is also known to con-
tain a nuclear localisation sequence (NLS), which, through
binding to importins [107], is further trafficked into the
nuclear compartment of the cell whereupon the anti-γH2AX
antibody can bind to its target.
It is important to note that the CPP does not impart speci-
ficity for any particular cancer biomarker and, therefore, it is
crucial that the whole antibody construct is able to be
externalised so that it can have further opportunity to reach
its target. An externalisation mechanism for the TAT protein
has been ascertained in a series of elegant experiments which
implicate binding to phosphatidylinositol-(4,5)-bisphosphate
on the inner leaflet of the cell membrane [108]. The net result
of these concurrent cellular import/export mechanisms is that
cells in a more active state of DNA damage repair will retain
the anti-γH2AX-TAT construct for longer time periods com-
pared with healthy cells with low basal expression levels of
γH2AX.
The addition of TAT to the antibody is typically achieved
using conventional EDC/sulfo-NHS coupling reagents which
promote the formation of an amide bond between the terminal
primary amine of TAT and any accessible carboxylic acid
residue on the antibody. Alternative bioconjugation methods
involving modification of carbohydrate groups on the Fc
chain have also been employed successfully [109].
Examples of γH2AX imaging with PET and SPECT
Our first report of a TAT-modified anti-γH2AX antibody
emerged in 2011 [110]. Here, the construct was labelled with
either a fluorophore or the SPECT radioisotope 111In. When
labelled with the fluorophore Alexa Fluor® 488 (λex/em: 495/
519 nm) this construct was shown in in vitro experiments to
gradually internalise over the course of 23 h into MDA-MB-
468 human breast cancer cells which had been exposed to
DNA damaging radiation (4 Gy). Promisingly, this compound
formed discrete foci within the nuclear compartment which
strongly co-localised with staining forγH2AX. The radioactive
111In-anti-γH2AX-TAT compound was also found to be
retained significantly longer within irradiated cells compared
with a series of experimental controls. The in vivo evaluation of
111In-anti-γH2AX-TAT showed an ability to track DNA dam-
age using a MDA-MB-468 xenograft tumour model in mice
(Fig. 9). Here, DNA damage within the tumours was induced
by either irradiation or via administration of bleomycin. In both
cases, higher uptake of 111In-anti-γH2AX-TAT was observed
in the tumours of mice that had received therapy. Taken
Fig. 9 Cornelissen et al. showed that uptake of 111In-anti-γH2AX-TAT in MDA-MB-468 breast cancer tumours increased following irradiation in a
dose-dependent manner. Reproduced with permission from [110]
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together, these experiments provided the first compelling evi-
dence of the feasibility of using CPP-modified antibody con-
structs to image intracellular DDR targets.
The ability of 111In-anti-γH2AX-TAT to image non-
invasively DDR during oncogenesis has since been evaluated
in a genetically engineered mouse model of HER2/neu-
overexpression driven breast cancer [111]. This model results
in the development of multiple palpable carcinomas in the mam-
mary fat pads when mice reach 130 days old. In a longitudinal
study, SPECT images were acquired on a weekly basis at 24 h
post-injection of 111In-anti-γH2AX-TAT. In SPECT images ac-
quired frommice between 76–110 days old, uptake of the radio-
tracer in the mammary fat pads was markedly higher compared
with a non-specific isotype-matched antibody which was mod-
ified in an identical manner. Immunohistochemical analysis of
resectedmammary fats pads showed that the number of γH2AX
foci per cell reached a peak within this age range and was sig-
nificantly greater compared with mice <76 or >106 days old.
Encouragingly, it was found that themedian time to the detection
of positive tissue with SPECT imaging (96 days) was much
earlier compared with the detection of lesions >150 μm by
DCE-MRI (120 days) or by palpation (131 days) (Fig. 10).
While advances in SPECT technology (specifically relat-
ing to improvements to collimators, quantitation, and recon-
struction software) are leading to a revival in this modalities
appeal, PET/CT imaging has gained acceptance as the stan-
dard of care in the management of cancer. This is due in part to
the high resolution and sensitivity that clinical PET has so far
offered compared with SPECT, and the ability during process-
ing of PET images to accurately correct for signal attenuation.
These important advantages have resulted in higher quality
images from which more meaningful data can be extracted.
Consequently, a PET radiotracer based on the anti-γH2AX-
TAT antibody construct has been developed containing the
radiometal zirconium-89.
The performance of 89Zr-anti-γH2AX-TAT has largely
shown consistencywith its indium-111 radiolabelled analogue
[112]. In cells exposed to DNA damaging radiation (4 Gy),
89Zr-anti-γH2AX-TAT exhibits considerably (eightfold) lon-
ger retention compared with control experiments involving
non-irradiated cells or a non-specific IgG. Furthermore, in
subcutaneous MDA-MB-468 xenograft tumours in mice,
higher uptake of 89Zr-anti-γH2AX-TAT (0.5 MBq, 5 μg)
was found following exposure to radiation (10 Gy) compared
with experimental controls (12.1 ± 1.6%ID/g, P < 0.001).
Radiotracers based on anti-γH2AX-TAT constructs have
shown promise in a variety of preclinical models based on
early detection and therapy evaluation. However, prior to clin-
ical translation, some important issues require consideration.
Firstly, it will be important to integrate a humanised version of
the anti-γH2AX antibody (the antibody used in these studies
is raised in rabbit) in order to prevent the invocation of an
immune response. Secondly, as non-specific tumour uptake
(resulting from the enhanced permeability and retention
[EPR] effect [113]) is responsible for a substantial contribu-
tion to overall tumour uptake, it will be desirable to amplify
γH2AX-mediated contrast. We hypothesise that this could be
achieved by improving delivery of the construct to tumours
by, for example, attachment of tumour-targeting peptides
[114]. This may also be achieved by reducing non-specific
uptake resulting from EPR by either using smaller antibody
fragments (minibodies, diabodies, etc.) [115] or by adopting a
pretargeted imaging approach [116].
Lastly, it is worth noting that γH2AX is a secondary mark-
er of DNA DSBs and its expression or foci number is not a
direct 1:1 measure of DSBs. This leads to difficulty in quan-
tifying precise numbers of DSBs that are being visualised
in vivo, especially when considering the relatively slow phar-
macokinetic profile of antibody-based imaging agents.
Therefore, it is important that the biology of yH2AX is taken
into account when interpreting images and image quantitation.
At present, no in vivo imaging modality exists that is suffi-
ciently sensitive to image the DSBs directly.
Conclusions
Our understanding of the cellular processes that are invoked in
response to DNA damage has improved considerably over
recent years. Advancements in this area have revealed attrac-
tive biomarkers, which could be used to improve upon
existing methods for non-invasive early cancer detection and
therapy evaluation. With these aims in mind, a range of PET/
SPECT imaging agents are currently under development and,
in some cases, are poised for evaluation in clinical settings. So
far, these imaging agents have mostly consisted of small mol-
ecule inhibitors of the PARP-1 enzyme or antibody-based
constructs targeting yH2AX.
Fig. 10 A Kaplan-Meier plot revealing that precancerous lesions and
tumours in BALB-neuT mice could be positively identified by 111In-
anti-γH2AX-TAT SPECT imaging at a younger age compared with
palpation or DCE MR imaging
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Most of the reports described herein have demonstrated the
ability to measure PARP-1 or yH2AX expression levels in
preclinical in vivo experiments and some studies have been
able to detect changes in expression following chemo- or ra-
diotherapy. While these findings are very promising, it should
be noted that uptake of these agents within tumours is gener-
ally low, particularly in comparison to what can often be
achieved through targeting of cancer biomarkers situated on
the cell-surface. This can be attributed to a variety of factors,
including the transient nature of DDR proteins, and the inef-
ficient internalisation/nuclear translocation of these agents.
While the first of these challenges is an inherent and unavoid-
able obstacle in this endeavour, the latter is an area which can
conceivably be improved upon through advances in the un-
derstanding of the various internalisation mechanisms and by
improved chemical design.
There is also a need to identify which of the multitude of
proteins involved in the DDR process represent the most valu-
able targets. This complex task will involve measuring
intranuclear concentrations of target proteins at various stages
during oncogenesis (as well as during cancer therapy), and
determining relative abundances in cancerous versus healthy
tissues. The duration of the targets’ existence is also an impor-
tant parameter, particularly if it will be used to assess DDR
activation following radiotherapy where expression levels of
many biomarkers, including PARP-1 and γH2AX, disappear
within days.
Of equal importance is the need to develop improved PET
and SPECT imaging agents which can bind to these targets
with high affinity and specificity, while also possessing the
necessary chemical properties that would promote efficient
cellular internalisation. Certainly, this will be aided by recent
advances in radiofluorination chemistry which allow far great-
er freedom in the design of novel PET radiotracers compared
to what has previously been possible with conventional
radiosynthetic approaches.
More broadly, non-invasive imaging of intracellular targets
is an important research endeavour with implications which
extend beyond imaging the DNA damage response. This abil-
ity also opens the door to a multitude of other intracellular
biomarkers with relevancy to additional aspects of cancer
biology.
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